Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

NCT04526704 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Tenosynovial Giant Cell Tumor

Interventions

DRUG: Pexidartinib

Sponsor

Daiichi Sankyo